Results of a Phase II trial with neoadjuvant chemotherapy in carcinoma of the cervix uteri

Sardi, Juan; Paola, Guillermo R. di; Giaroli, Adolfo; Sananes, Carlos; Rueda, Nidia Gomez; Cachau, Alberto; Vighi, Susana; Burlando, Silvia

doi:10.1016/s0090-8258(88)80002-7

Cited by 32 publications

(10 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This produced a satisfactory reduction in tumor size, which made surgical resection possible in previously inoperable cases, and the toxicity was acceptable. These patients attained a superior survival compared to those receiving only conventional therapy (4). Color Doppler ultrasound and magnetic resonance imaging (MRI) have been tested as evaluators and predictors of response to neoadjuvant chemotherapy (NACT) (5,6), but the results are still controversial.…”

Section: Introductionmentioning

confidence: 94%

Power Doppler vascularity index for predicting the response of neoadjuvant chemotherapy in cervical carcinoma

Chen

Cheng

Lee

et al. 2004

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 94%

Power Doppler vascularity index for predicting the response of neoadjuvant chemotherapy in cervical carcinoma

Chen

Cheng

Lee

et al. 2004

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

show abstract

“…It is worthwhile to note that only one patient had microscopic disease at parametria despite seven of these impressed clinically with parametrial disease. This lack of correspondence between clinical and pathological parametrial infiltration has already been observed (27) , and this suggested that response to chemo-therapy follows a centripetal pattern, meaning that all cases responding at the primary tumor have parametrial response. Thus, the clinical suspicion of parametrial disease should not contraindicate a radical hysterectomy.…”

Section: Discussionmentioning

confidence: 67%

Type III radical hysterectomy after induction chemotherapy for patients with locally advanced cervical carcinoma

López-Graniel¹,

Reyes²,

Chanona³

et al. 2001

Int J Gynecol Cancer

View full text Add to dashboard Cite

Neoadjuvant chemotherapy followed by surgery is a promising approach in locally advanced cervical carcinoma. The aim of this study was to evaluate the feasibility, technical aspects, and clinical results of surgery after induction chemotherapy in this patient population. Forty-one untreated cervical carcinoma patients staged as IB2 to IIIB received three 21-day courses of cisplatin 100mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1 and 8 followed by surgery or concomitant chemoradiation. The response to chemotherapy, operability, surgical/pathological findings, disease-free period, and survival of the surgically treated patients were evaluated. All 41 patients were evaluated for toxicity and 40 were evaluated for response. The overall objective response rate was 95% (95% confidence interval 88%-100%), and was complete in three patients (7.5%) and partial in 35 (87.5%). Granulocytopenia grades 3/4 occurred in 13.8% and 3.4% of the courses, respectively, whereas nonhematological toxicity was mild. Twenty-three patients underwent type III radical hysterectomy. Mean duration of surgery was 3.8 h (range 2:30-5:20), median estimated blood loss was 670 ml and median hospital stay was 5.2 days. Intraoperative complications occurred in one case (venous injury). In all but one case the resection margins were negative. Four patients (17%) had positive nodes (one node each); six (26%) had complete pathologic response, three (13%) had microscopic; and 14 (60%) macroscopic residual disease. At 24 months of maximum follow-up (median 20), the disease-free and overall survival rates were 59% and 91%, respectively. Induction chemotherapy with cisplatin/gemcitabine produced a high response rate and did not increase the difficulty of surgery. Operating time, blood loss, intraoperative complications, and hospital stay were all within the range observed for type III hysterectomy in early stage patients. We therefore conclude that type III radical hysterectomy is feasible in locally advanced cervical cancer patients who respond to chemotherapy.

show abstract

“…The results of Panici et al (14) obtained in stages IB-111 with chemotherapy (cisplatin, methorexate and bleomycin) and followed by surgery in responders showed CR in 10 cases (16'%1) and PR in 42 (68%) at histologic examination. High response rates were also reported with VBP (vinblastine, bleomycin and cisplatin) in stages IB and 11 (15,16). A relationship between chemotherapy failures and radioresistance has been observed.…”

Section: Discussionmentioning

confidence: 88%

Chemotherapy And Radiotherapy In Locally Advanced Cervical Cancer

et al. 1995

View full text Add to dashboard Cite

Results of a Phase II trial with neoadjuvant chemotherapy in carcinoma of the cervix uteri

Cited by 32 publications

References 2 publications

Power Doppler vascularity index for predicting the response of neoadjuvant chemotherapy in cervical carcinoma

Power Doppler vascularity index for predicting the response of neoadjuvant chemotherapy in cervical carcinoma

Type III radical hysterectomy after induction chemotherapy for patients with locally advanced cervical carcinoma

Chemotherapy And Radiotherapy In Locally Advanced Cervical Cancer

Contact Info

Product

Resources

About